RANGING OF ANTIPHOSPOLIPID ANTIBODIES IN THE PATIENTS WITH THROMBOPHILIA AND RECURRENT MISCARRIAGE

Laboratory diagnosis of antiphospholipid syndrome (APS) is based on detection of antiphospholipid antibodies (aPLs). E.g., aPLs are directed against conformational epitopes of the so-called “co-factor” proteins: β2-gycoprotein 1 (β2-GP1), annexin V (An V) and prothrombin (Pt) that are formed during interaction with phospholipids – cardiolipin (CL), phosphatic acid (Pha), phosphatidylcholine (Pch), phosphatidylethanolamine (Pe), phosphatidylglycerol (Pg), phosphatidylinositol (Pi), phosphatidylserine (Ps). A routine methodology of detection based on ELISA testing is challenged by new tests when the antigen is absorbed on another kind of support like microbeads or membranes that can influence density of conformational epitopes for aPL’s binding. The aim of our study was to compare the results of aPLs detection by ELISA and multi-line immunodot assay (MLD).
We collected blood serum samples from 45 patients with noncardioembolic ischemic strokes, 19 patients with recurrent deep vein thrombosis of lower limbs, 44 females with recurrent miscarriages, and 50 clinically healthy donors. To compare the results of aPL detection by ELISA and MLD kits, the test systems from different manufacturers were evaluated. We used an ELISA kits for detection of antibodies to CL IgG, aCL IgM, β2-GP1 produced by Euroimmun AG (Mr1) and Orgentec Diagnostica GmbH (Mr2) and MLD – for detection of antibodies to CL, β2-GP1, Pch, Pe, Pg, Pi, Ps, AnV and Pt (Medipan GmbH, Mr3).
When a cut-off titer was used as the main index, 30.5% of patients were aPLs-positive with ELISA method by Mr1 and 38%, wiht Mr2. By MLD aPls were detected in 30% of patients. In the same cohort, medium and high aPLs titers (> 40 U/mL) were determined in 12% of patients using ELISA kits. Positive and highly positive aPLs titers were determined in 16% when using a new method by Mr3. Medium and high titer were detected only for antibodies to β2-GP1, CL, An V, Pha and Phs.
The use of ELISA approach for detection of aPLs in patients with thrombosis and obstetric pathology is associated with relatively high number of low-positive ELISA results. Due to higher sensitivity for medium and high aPLs titers, MLD testing may be used as a confirming method for APS diagnosis.

1. Lapin S.V., Mazing A.V., Bulgakova T.V., Maslyansky A.L., Ilivanova E.P., Kozarenko A.А., Totolian A.A. Analytical and diagnostic characteristics of the domestic test system for detection of antibodies to cyclic citrulline peptide. Klinicheskaya laboratornaya diagnostika = Russian Clinical Laboratory Diagnostics, 2011, no. 12, pp. 12-17. (In Russ.)

2. Lapin S.V., Totolian A.A. Immunological laboratory diagnostics of autoimmune diseases. St. Petersburg: Chelovek, 2006. 128 p.

3. Lapin S.V., Totolian A.A. Immunological laboratory diagnostics of autoimmune diseases. St. Petersburg: Chelovek, 2006. 272 p.

4. Sozina A.V., Ilivanova E.P., Shulman A.M., Shulman M.A., Shemerovskaya T.G., Lapin S.V., Totolian A.A. Clinical and diagnostic significance of detection of the antinuclear factor, antibodies to double-stranded DNA and cardiolipin in patients with systemic lupus erythematosus. Klinicheskaya laboratornaya diagnostika = Russian Clinical Laboratory Diagnostics, 2008, no. 5, pp. 44-47. (In Russ.)

5. Sozina A.V., Neustroeva Yu.A., Tikhomirova T.A., Lapin S.V. Combined prevalence of autoantibodies in patients with diffuse connective tissue diseases. Meditsinskaya immunologiya = Medical Immunology (Russia), 2007, Vol. 9, no. 1, pp. 69-76. (In Russ.) doi: 10.15789/1563-0625-2007-1-69-76.

6. Roggenbuck D., Schierac P., Sack U., Lapin S.V., Mazing A.V., Totolian A.A. Novel methods for autoantibody detection in laboratory diagnostics of autoimmune rheumatic diseases. Meditsinskaya immunologiya = Medical Immunology (Russia), 2014, Vol. 16, no. 3, pp. 221-226. (In Russ.) doi: 10.15789/1563-0625-2014-3-221-226.

7. Tkachenko O.Yu., Lapin S.V., Mazing A.V., Lazareva N.M., Shmonin A.A., Solovyova L.N., Bondareva E.A., Selkov S.A., Chepanov S.V., Totolian A.A. The comparative analysis of immunologic techniques of detection of antiphospholipid Antibodies. Klinicheskaya laboratornaya diagnostika = Russian Clinical Laboratory Diagnostics, 2017, Vol. 62, no. 1, pp. 40-44. (In Russ.)

8. Ambrosino P., Lupoli R., Spadarella G., Tarantino P., di Minno A., Tarantino L., di Minno M.N. Autoimmune liver diseases and antiphospholipid antibodies positivity: A meta-analysis of literature studies. J. Gastrointest. Liver Dis., 2015, Vol. 24, no. 1, pp. 25-34.

9. Dalekos G.N., Zachou K., Liaskos C. The antiphospholipid syndrome and infection. Curr. Rheumatol. Rep., 2001, Vol. 3, no. 4, pp. 277-285.

10. Devreese K.M., Pierangeli S.S., de Laat B., Tripodi A., Atsumi T., Ortel T.L.; Subcommittee on Lupus Anticoagulant/Phospholipid/Dependent Antibodies. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the IS TH. J. Thromb. Haemost., 2014, Vol. 12, no. 5, pp. 792-795.

11. Egerer K., Roggenbuck D., Büttner T., Lehmann B., Kohn A., von Landenberg P., Hiemann R., Feist E., Burmester G.R., Dörner T. Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. Arthritis Res. Ther., 2011, Vol. 13, no. 4, R118. doi: 10.1186/ar3421.

12. Galli M., Comfurius P., Maassen C., Hemker H.C., de Baets M.H., van Breda-Vriesman P.J., Barbui T., Zwaal R.F., Bevers E.M. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet, 1990, Vol. 335, no. 8705, pp. 1544-1547.

13. Harris E.N., Gharavi A.E., Boey M.L., Patel B.M., Mackworth-Young C.G., Loizou S., Hughes G.R. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet, 1983, Vol. 322, no. 8361, pp. 1211-1214.

14. Jeleniewicz R., Majdan M., Targońska-Stępniak B., Dryglewska M. Prevalence of antiphospholipid antibodies in rheumatoid arthritis patients and relationship with disease activity. Pol. Arch. Med. Wewnętrznej, 2012, Vol. 122, no. 10, pp. 480-486.

15. Krilis S.A., Giannakopoulos B. Laboratory methods to detect antiphospholipid antibodies. Hematology Am. Soc. Hematol. Educ. Program, 2014, Vol. 2014, no. 1, pp. 321-328.

16. Meroni P., Chighizola C., Rovelli F., Gerosa M. Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res. Ther., 2014, Vol. 16, no. 2, p. 209.

17. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat. Rev. Rheumatol., 2011, Vol. 7, no. 6, pp. 330-339.

18. Misasi R., Capozzi A., Longo A., Recalchi S., Lococo E., Alessandri C., Conti F., Valesini G., Sorice M. New antigenic targets and methodological approaches for refining laboratory diagnosis of antiphospholipid syndrome. J. Immunol. Res., 2015, Vol. 2015, 858542. doi:10.1155/2015/858542.

19. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., Derksen R.H., de Groot P.G., Koike T., Meroni P.L., Reber G., Shoenfeld Y., Tincani A., Vlachoyiannopoulos P.G., Krilis S.A. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Thromb. Haemost., 2006, Vol. 4, no. 2, pp. 295-306.

20. Neville C., Rauch J., Kassis J., Chang E.R., Joseph L., le Comte M., Fortin P.R. Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies. Thromb. Haemost., 2003, Vol. 90, no. 1, pp. 108-115.

21. Otomo K., Atsumi T., Amengual O., Fujieda Y., Kato M., Oku K., Horita T., Yasuda S., Koike T. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum., 2012, Vol. 64, no. 2, pp. 504-512.

22. Pengo V., Biasiolo A., Pegoraro C., Cucchini U., Noventa F., Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb. Haemost., 2005, Vol. 93, no. 6, pp. 1147-1152.

23. Pengo V., Ruffatti A., Legnani C., Testa S., Fierro T., Marongiu F., de Micheli V., Gresele P., Tonello M., Ghirarduzzi A., Bison E., Denas G., Banzato A., Padayattil Jose S., Iliceto S. Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile: a multicenter prospective study. Blood, 2011, Vol. 118, no. 17, pp. 4714-4718.

24. Petri M., Orbai A.M., Alarcón G.S., Gordon C., Merrill J.T., Fortin P.R., Bruce I.N., Isenberg D., Wallace D.J., Nived O., Sturfelt G., Ramsey-Goldman R., Bae S.C., Hanly J.G., Sánchez-Guerrero J., Clarke A., Aranow C., Manzi S., Urowitz M., Gladman D., Kalunian K., Costner M., Werth V.P., Zoma A., Bernatsky S., Ruiz-Irastorza G., Khamashta M.A., Jacobsen S., Buyon J.P., Maddison P., Dooley M.A., van Vollenhoven R.F., Ginzler E., Stoll T., Peschken C., Jorizzo J.L., Callen J.P., Lim S.S., Fessler B.J., Inanc M., Kamen D.L., Rahman A., Steinsson K., Franks A.G. Jr, Sigler L., Hameed S., Fang H., Pham N., Brey R., Weisman M.H., McGwin G. Jr, Magder L.S. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum., 2012, Vol. 64, no. 8, pp. 2677-2686.

25. Ruiz-Irastorza G., Crowther M., Branch W., Khamashta M.A. Antiphospholipid syndrome. Lancet, 2010, Vol. 376, no. 9751, pp. 1498-1509.

26. Sciascia S., Sanna G., Murru V., Roccatello D., Khamashta M.A., Bertolaccini M.L. The global antiphospholipid syndrome score in primary APS. Rheumatol. (United Kingdom), 2014, Vol. 54, no. 1, pp. 134-138.

27. Touré A.O., Ly F., Sall A., Diatta A., Gadji M., Seck M., Faye B., Dieye T., Diop S. Antiphospholipid antibodies and systemic scleroderma. Turkish J. Haematol., 2013, Vol. 30, no. 1, pp. 32-36.

28. Zhou Y., Ying Z., Li R., Zhu J., Li Z. Clinical and immunological relevance of antiphospholipid antibodies in patients with lymphoma. Zhonghua Yi Xue Za Zhi, 2011, Vol. 91, no. 37, pp. 2607-2610.